BeginnerLive ClassesNo New Dates

Introduction to Ketamine-Assisted Therapy

Introduction to Ketamine provides clinicians with foundational knowledge of ketamine-assisted psychotherapy. It covers basic pharmacology, therapeutic mechanisms, practical administration, and key safety and ethical considerations.

Provider

Fluence

English

Schedule

5 hours

Enrollment

$375

Course Overview

The Introduction to Ketamine course offers a foundational understanding of ketamine-assisted psychotherapy for clinicians. This program covers the basic pharmacology of ketamine, its therapeutic mechanisms, and the potential benefits and risks associated with its use. Participants will engage in live online sessions, interactive discussions, and case studies, providing a comprehensive overview of the practical and ethical considerations involved in ketamine therapy.

Over several weeks, the course includes detailed instruction on how to screen and prepare clients, administer ketamine in a therapeutic setting, and integrate the experiences into ongoing therapy. Emphasis is placed on creating a safe and supportive environment for clients, understanding the nuances of dosing and administration, and managing potential adverse effects. Participants will also learn about the latest research and evolving best practices in the field.

By the end of the course, clinicians will have the knowledge and confidence to incorporate ketamine-assisted psychotherapy effectively into their practice. They will be equipped to support clients through the preparation, administration, and integration phases, ensuring a holistic approach to mental health care.

Who is this for?

clinicians

Prerequisites

null

About the Provider

Fluence is a psychedelic therapy education company co-founded by psychologists Dr. Ingmar Gorman and Dr. Elizabeth Nielson, offering continuing education courses and a Certificate in Psychedelic Therapy and Integration for licensed therapists and advanced graduate students. Having trained 8,000+ clinicians, Fluence draws on its founders' direct experience in FDA-approved Phase 3 clinical trials of MDMA- and psilocybin-assisted therapies.

Related Courses

View all courses